Aflac Incorporated Β· AFL
Aflac's higher Japan margin guidance comes from its yearly reserve review
Aflac's raised Japan outlook reflects the annual re-estimate of future claims; without it, adjusted earnings per share were flat, leaving growth to investments, freed capital and buybacks.
3 min read Published on Updated on
Published by
Inve Content team
Aflac Incorporated stock page β More news from Nov 11, 2026
Aflac raised its profit-margin guidance for Japan on 5 November and said the year's benefit ratio there, claims paid as a share of premiums, would finish slightly below the range it set in February. Nearly all of that change is the company's annual actuarial review, a once-a-year re-estimate of future claims that lands in the third quarter. Take the review out and adjusted earnings per share were level with a year earlier.
Max Broden, the chief financial officer, gave the new figure: "we have raised the 2026 expected pretax profit margin range for Aflac Japan to 35% to 38%." It is the same range the company gave for 2025 after that year's review, and higher than the one it set in February. Japan, where Aflac sells cancer and medical cover, earns most of the group's profit, so these ranges are the ones holders watch.
The review works through reserves, the money set aside for future claims on policies already sold. When the company expects fewer claims than it had assumed, it releases part of those reserves, and the release shows up as lower benefits in the quarter. This year the release added $0.71 to adjusted earnings per share, a little less than the year before.
Without the yearly reserve review, adjusted EPS was flat against the same quarter a year earlier
$
As reported
- $2.49 Q3 2025
- $2.43 Q3 2026
Excluding the review
- $1.73 Q3 2025
- $1.72 Q3 2026
The change was flagged in advance. In August, with Japan's first-half ratio running slightly above its range, Broden guided to the high end of that range and said the outlook left out the third-quarter review. A year earlier he had said the company's ranges generally exclude further unlocks. So the November guidance is the review flowing into numbers that were set without it. Management's own estimate for the quarter, stripping out both the review and the quarter's own claims experience, sits inside the range, while the reported ratio falls far below it.
Japan's claims ratio sits inside February's 60%-63% range once the reserve review is taken out
%
- Last quarter, reported 49.2%
- Last quarter, adjusted by management 61.7%
- Nine months, reported 58.8%
- Nine months without the review (estimate) 62.8%
Part of the review does carry forward. Broden said the company lowered the share of each Japan premium it reserves for expected claims, which should keep the benefit ratio on existing policies about 70 basis points lower from the fourth quarter. He traced the gains to the cancer book, where more deaths from other causes mean fewer expected cancer claims. That improvement lasts, but it is small beside the one-time release.
With the claims year running about where it was guided and Japan premiums shrinking in yen, growth in earnings per share has to come from elsewhere. Selling and replacing bonds in the Japan portfolio has added over $80 million of annual investment income this year, though Bradley Dyslin, the global chief investment officer, said "it's going to be difficult to have the same level of impact that we've had so far." Moving more cancer reserves to Aflac's Bermuda reinsurer should release capital over time, and buybacks cut the diluted share count, which is why adjusted earnings in dollars fell more than per-share earnings did.
The flat comparison is not exact. The latest quarter also carried cybersecurity costs in Japan and investment income below the company's long-run expectation. Adding those back would put underlying earnings per share a little ahead of a year earlier, a modest gain rather than a better year for claims in Japan.
Aflac Incorporated stock page β
The record: full financial tables
Financials
Income statement, last 8 quarters
| Quarter end | Sales | YoY | PBT | Net profit |
|---|---|---|---|---|
| Sep 2026 | 3,271 | β31.0% | 500 | 303 |
| Jun 2026 | 4,117 | β1.0% | 995 | 825 |
| Mar 2026 | 4,346 | +27.9% | 1,225 | 1,019 |
| Dec 2025 | 4,866 | β10.0% | 1,572 | 1,379 |
| Sep 2025 | 4,740 | +60.7% | 1,994 | 1,639 |
| Jun 2025 | 4,160 | β19.0% | 822 | 599 |
| Mar 2025 | 3,398 | β37.5% | 145 | 29 |
| Dec 2024 | 5,404 | +43.1% | 2,136 | 1,902 |
Balance sheet
| As of | Equity | Cash | Fixed assets | Total assets |
|---|---|---|---|---|
| Sep 2026 | 29,283 | 5,623 | 356 | 113,511 |
| Jun 2026 | 30,312 | 6,120 | 351 | 115,961 |
| Mar 2026 | 29,961 | 5,654 | 354 | 116,280 |
| Dec 2025 | 29,490 | 6,245 | 351 | 116,470 |
Cash flow
| Year end | Operating | Investing | Financing |
|---|---|---|---|
| Dec 2025 | 2,555 | 1,561 | β4,069 |
| Dec 2024 | 2,707 | 2,781 | β3,486 |
| Dec 2023 | 3,190 | 817 | β3,723 |
| Dec 2022 | 3,879 | β1,540 | β3,551 |